Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study

[1]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[2]  J. Chandler,et al.  Low bone mineral density and risk of fracture in white female nursing home residents. , 2000, JAMA.

[3]  Ego Seeman,et al.  Differing effects of denosumab and alendronate on cortical and trabecular bone. , 2014, Bone.

[4]  J. Westbrook,et al.  Anti-osteoporosis Medication Use in a High Fracture-Risk Population: Contemporary Trends in Australian Residential Aged Care Facilities , 2019, Health services insights.

[5]  Predictors of Hip Fracture Despite Treatment with Bisphosphonates among Frail Older Adults , 2020, Journal of the American Geriatrics Society.

[6]  I. Reid,et al.  Fracture Prevention with Zoledronate in Older Women with Osteopenia , 2018, The New England journal of medicine.

[7]  T. Travison,et al.  Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting , 2018, Archives of Osteoporosis.

[8]  Janette D Lie,et al.  Osteoporosis: A Review of Treatment Options. , 2018, P & T : a peer-reviewed journal for formulary management.

[9]  Jacques P. Brown,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  Mary Jordan Samuel.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2015, Journal of the American Geriatrics Society.

[11]  D. Solomon,et al.  Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use. , 2019, The Journal of clinical endocrinology and metabolism.

[12]  J. Lewis,et al.  Identifying newly approved medications in Medicare claims data: a case study using tocilizumab , 2013, Pharmacoepidemiology and drug safety.

[13]  Fares Alahdab,et al.  Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. , 2019, The Journal of clinical endocrinology and metabolism.

[14]  D. Kiel,et al.  Fracture Risk Assessment in Long-term Care (FRAiL): Development and Validation of a Prediction Model , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  Geographic Variation in Hip Fracture Among United States Long-Stay Nursing Home Residents. , 2016, Journal of the American Medical Directors Association.

[16]  W. Ray,et al.  Identification of fractures from computerized Medicare files. , 1992, Journal of clinical epidemiology.

[17]  M. Bouxsein,et al.  Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA‐HRpQCT Study , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  P. Juneau,et al.  Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States , 2017, Archives of Osteoporosis.

[19]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[20]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[21]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[22]  A. Díez-Pérez,et al.  Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis , 2019, Osteologie.

[23]  D. Berlowitz,et al.  Overview of significant changes in the Minimum Data Set for nursing homes version 3.0. , 2012, Journal of the American Medical Directors Association.

[24]  Kenneth Rockwood,et al.  Frailty defined by deficit accumulation and geriatric medicine defined by frailty. , 2011, Clinics in geriatric medicine.

[25]  S. Cummings,et al.  Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. , 2011, The Journal of clinical endocrinology and metabolism.

[26]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[27]  L. Zhou,et al.  Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post‐menopausal osteoporosis , 2016, Journal of clinical pharmacy and therapeutics.

[28]  D. Kiel,et al.  Facility and State Variation in Hip Fracture in U.S. Nursing Home Residents , 2018, Journal of the American Geriatrics Society.

[29]  J. Robins,et al.  Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators , 2016, EGEMS.

[30]  Jennifer L. Lund,et al.  Comparison of SEER Treatment Data With Medicare Claims , 2016, Medical care.

[31]  L. Ferrucci,et al.  Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

[32]  Hang Lee,et al.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial , 2013, The Lancet.

[33]  D. Kiel,et al.  Secular Trends in the Incidence of Hip Fracture Among Nursing Home Residents , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  S. Mitchell,et al.  Potentially burdensome end‐of‐life transitions among nursing home residents with poor‐prognosis cancer , 2019, Cancer.

[35]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[36]  K. Saag,et al.  Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab , 2015, Arthritis & rheumatology.

[37]  S. Perera,et al.  Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. , 2015, JAMA internal medicine.

[38]  D. Kiel,et al.  Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults , 2019, Journal of the American Geriatrics Society.

[39]  B. Zarowitz,et al.  Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis. , 2015, Journal of the American Medical Directors Association.

[40]  D. Kiel,et al.  Incidence of Hip Fracture in U.S. Nursing Homes. , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[41]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[42]  D. Kiel,et al.  Defining hip fracture with claims data: outpatient and provider claims matter , 2017, Osteoporosis International.

[43]  Susan C. Miller,et al.  The residential history file: studying nursing home residents' long-term care histories(*). , 2011, Health services research.